STALICLA SA
STALICLA SA is a Swiss clinical-stage biotech developing precision treatments for neurodevelopmental and neuropsychiatric disorders. Its lead assets, STP1 and a second NDD compound, are entering Phase 2 trials. STP7 (Mavoglurant) is progressing to Phase 3 with full US government funding. STALICLA is currently raising a $60M Series C to support Phase 2 development.
Date, time and room information
May 6, 15:30 - 15:45, room Montreal
Category
Clinical stage development company
Speaker information
| Name | Position | Institution |
|---|---|---|
| Lynn Durham | CEO & Founder |
